

Muntasir Mamun Majumder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5052865/publications.pdf>

Version: 2024-02-01

38
papers

1,828
citations

706676

14
h-index

721071

23
g-index

41
all docs

41
docs citations

41
times ranked

3999
citing authors

#	ARTICLE	IF	CITATIONS
1	The Peptideâ€“Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. <i>HemaSphere</i> , 2022, 6, e687.	1.2	3
2	Quantitative online survey of self-perceived knowledge and knowledge gaps of medicines research and development among Finnish general public. <i>BMJ Open</i> , 2022, 12, e053693.	0.8	2
3	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. <i>Cancers</i> , 2021, 13, 1527.	1.7	29
4	Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. <i>Scientific Reports</i> , 2021, 11, 12866.	1.6	8
5	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723016.	1.8	5
6	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	1.7	19
7	Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006752.	1.5	106
8	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	3.3	40
9	Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge. <i>Bioinformatics</i> , 2018, 34, i395-i403.	1.8	6
10	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264.	0.6	5
11	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cellâ€“induced protection of AML. <i>Blood</i> , 2017, 130, 789-802.	0.6	90
12	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	0.8	35
13	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. <i>Oncotarget</i> , 2017, 8, 103731-103743.	0.8	19
14	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527.	0.8	28
15	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. <i>Blood</i> , 2016, 128, 4711-4711.	0.6	0
16	Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies. <i>Blood</i> , 2016, 128, 3515-3515.	0.6	0
17	DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. <i>Blood</i> , 2016, 128, 198-198.	0.6	0
18	Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. <i>Blood</i> , 2015, 126, 3006-3006.	0.6	0

#	ARTICLE	IF	CITATIONS
19	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. <i>Blood</i> , 2015, 126, 2462-2462.	0.6	0
20	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. <i>Blood</i> , 2015, 126, 867-867.	0.6	0
21	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	1.6	243
22	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. <i>Blood</i> , 2014, 124, 2160-2160.	0.6	0
23	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505.	0.6	0
24	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. <i>Blood</i> , 2014, 124, 2203-2203.	0.6	3
25	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046.	0.6	3
26	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. <i>Blood</i> , 2014, 124, 646-646.	0.6	0
27	Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. <i>Blood</i> , 2014, 124, 1771-1771.	0.6	0
28	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. <i>Blood</i> , 2014, 124, 3351-3351.	0.6	0
29	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
30	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. <i>Blood</i> , 2013, 122, 1668-1668.	0.6	0
31	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	0.6	0
32	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. <i>Blood</i> , 2013, 122, 2719-2719.	0.6	0
33	Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. <i>Nucleic Acids Research</i> , 2012, 40, 6585-6594.	6.5	63
34	Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913.	13.9	681
35	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	0.6	1
36	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Methylated DNA Causes a Physical Block to Replication Forks Independently of Damage Signalling, O6-Methylguanine or DNA Single-Strand Breaks and Results in DNA Damage. <i>Journal of Molecular Biology</i> , 2010, 402, 70-82.	2.0	64
38	Analgesic and Antioxidant Activity of the Hydromethanolic Extract of <i>Mikania scandens</i> (L.) Willd. Leaves. <i>American Journal of Pharmacology and Toxicology</i> , 2009, 4, 1-7.	0.7	36